OncoMatch/Clinical Trials/NCT04874038
Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN)
Is NCT04874038 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Lidocaine 20mg/ml for post-mastectomy pain syndrome.
Treatment: Lidocaine 20mg/ml — Phase III, international multicentre, parallel group, blinded, 1:1 randomized controlled trial to determine the effect of an intraoperative intravenous lidocaine infusion on reducing the development of persistent pain 3-months after breast cancer surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: BRCA1 any tested
including prophylactic surgery (e.g., family history or BRCA gene mutation)
Allowed: BRCA2 any tested
including prophylactic surgery (e.g., family history or BRCA gene mutation)
Demographics
Prior therapy
Cannot have received: breast surgery
Previous breast surgery within 6 months of index surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04874038 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior breast surgery disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages